Nevro stock

IPSIS: Formerly the Spine Intervention Society
This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
G

gaspasser127

Full Member
Verified Member
Physician
7+ Year Member
Joined
Apr 19, 2016
Messages
395
Reaction score
330
Down 40% a couple days ago
Around the $5 mark now
$200M market cap
Revised guidance for remainder of 2024 is lowered

Nevro argues they have $270M in the bank and that they have battery replacements that are probably coming up soon as well as increasing SIJ fusion business.

Thoughts?
Members don't see this ad.
 
I trained in SIJ fusion with them. Slick device. Cannot figure out who needs this surgery.
And why cant I just turf it to NS or Ortho spine.

Hate that they are decimated. Maybe Stryker will buy them for fire sale prices. Half their C suite is from Stryker now.
 
It looks like they have had excellent attendance at their SI fusion trainings and there seems to be a lot of cases being done per local rep chatter and what I have seen on LinkedIn. But those trainings cost a huge sum of money so one would assume the trainings cost a lot more than any 2024 revenue they might generate. At least with the SI product you don’t have to worry about placing an orphan system in someone like happened with Nuvectra.
 
Members don't see this ad :)
$200M market cap is tiny though. That is rather shocking. An individual pain doc could conceivably buy 1% if so inclined. They are going to end up paying $75M for Vyrsa if they don’t go bankrupt prior to Vyrsa hitting the sales number goals.
 
Sacrix, Transloc 3d etc all are pretty good also. You can probably use Vyrsa screws transileal oblique also but the reps won’t be able to help. I liked the Vyrsa bone graft a lot when you could use it as 27279. W
 
As we all know the SIJ space is extremely saturated. The 27278 code is difficult to get covered by most insurances and payors are getting increasingly particular about 27279 and requiring a true lateral fusion. I think it’s unrealistic to expect enough Vyrsa business for them to make up for significantly lost revenue.

200M market cap is abysmal.

At what point do we say there’s enough concern about the long term viability of this company that we’re concerned about implanting their IPGs in our patients?
 
gaspasser127 said:
At what point do we say there’s enough concern about the long term viability of this company that we’re concerned about implanting their IPGs in our patients?
Click to expand...
I stopped using them about a year ago for this reason, after it seemed like they were never going to bounce back
 
I looked over everything again. There is no way for si fusion to save them. Once they get to $10M Vyrsa sales they will pay $10M out to the Vyrsa owners and once they get to $20M they will pay another $10M. So not only are they bankrolling the sales force and training but they will get nothing from the first $20M in sales. I guess they could try to renegotiate with the biggest former owners of Vyrsa and draw out the terms for those individuals.
 
lobelsteve said:
I trained in SIJ fusion with them. Slick device. Cannot figure out who needs this surgery.
And why cant I just turf it to NS or Ortho spine.

Hate that they are decimated. Maybe Stryker will buy them for fire sale prices. Half their C suite is from Stryker now.
Click to expand...

Steve, is nevro still your scs of choice?
 
lobelsteve said:
I trained in SIJ fusion with them. Slick device. Cannot figure out who needs this surgery.
And why cant I just turf it to NS or Ortho spine.

Hate that they are decimated. Maybe Stryker will buy them for fire sale prices. Half their C suite is from Stryker now.
Click to expand...

It’s cheap enough to be bought by Stryker but would be fundamentally an outlier in their product portfolio.

My Stryker rep told me a couple weeks ago that in one of their sales meetings and question was brought up and executive leadership told them they had no interest in buying a stim company.

Maybe it’s different now with a 200M valuation?
 
gaspasser127 said:
It’s cheap enough to be bought by Stryker but would be fundamentally an outlier in their product portfolio.

My Stryker rep told me a couple weeks ago that in one of their sales meetings and question was brought up and executive leadership told them they had no interest in buying a stim company.

Maybe it’s different now with a 200M valuation?
Click to expand...
It's the workforce obligation that would give me pause coming from a structural spine perspective. It's an expensive thing to have all these reps, clinical supports, phone banks managing devices that are implanted in patients whose experience changes the outcome of the device. It becomes a very expensive staffing proposition to keep placebo from becoming a nocebo.
 
retrospective review of data from the previous PDN study, so if there was bias in that study, that bias is carried over.

study designed to look at those who got the 10 KHz SCS. a small number of people did not cross over. this study did not compare these indices to those who failed SCS trial or those who did not cross over, so it is unknown if SCS was better than no implant or traditional. just that the numbers seemed to get better in those who got 10 Khz SCS.
 
You must log in or register to reply here.
Top